Most Read Articles
Pearl Toh, 27 Mar 2020
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 31 Mar 2020
Treatment with hydroxychloroquine appears to significantly reduce viral load in patients with the novel coronavirus disease (COVID-19), with its beneficial effects reinforced by adding azithromycin, results of a recent study have shown.
Elvira Manzano, 22 Nov 2017
A blood pressure (BP) reading of 130/80 mm Hg or higher is the ‘new high’ in the latest AHA/ACC* hypertension guidelines, a threshold that is tighter than the JNC 7** cutpoint of 140/90 mm Hg for stage 1 hypertension in the general population. The change will mean more patients being labelled with hypertension.
Audrey Abella, 27 Mar 2020
The angiotensin receptor blocker (ARB) losartan did not improve inflammation, T-cell immune recovery, or fibrotic activity among older persons living with HIV (PLHIV) and viral suppression, according to data presented at CROI 2020.

Female gender, dosage predict gastrin elevation in GERD patients on long-term PPI therapy

13 Feb 2020

Dosage and female gender are associated with the development of gastrin elevation following proton pump inhibitor (PPI) therapy, a recent study has found. Moreover, fasting serum gastrin significantly correlates with PPI dosage over weight and over body surface area.

This cross-sectional study sought to determine the most important predictors for gastrin elevation in patients on long-term PPI therapy through analysis of data from two published studies in Icelandic patients with endoscopically verified erosive gastro-oesophageal reflux disease (GERD).

The investigators compared PPI exposure in dosage over weight (mg/kg) and dosage over body surface area (mg/m2) with fasting gastrin levels in two separate multiple linear regression models. They also obtained data on age, gender, weight, smoking, H. pylori infection, and PPI duration and type.

Analysis was conducted in 157 patients (78 females). Females had significantly higher median serum gastrin levels than males (92 vs 60 pg/mL; p=0.001). In simple linear regression, serum gastrin levels was associated with gender (p=0.0008) and PPI exposure in mg/kg (p=0.0001) and mg/m2 (p=0.0001).

In multiple linear regression, higher gastrin values were predicted by PPI exposure, both in mg/kg (β, 0.95, 95 percent confidence interval [CI], 0.4–1.5; p=0.001) and mg/m2 (β, 0.02, 95 percent CI, 0.0–0.0; p=0.0015) and female gender (β, 0.2, 95 percent CI, 0.0–0.4; p=0.02).

“Gastrin elevation is a known but variable consequence of PPI therapy,” the investigators noted. “Concerns have been raised about the clinical importance of chronic PPI induced gastrin elevation.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 27 Mar 2020
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 31 Mar 2020
Treatment with hydroxychloroquine appears to significantly reduce viral load in patients with the novel coronavirus disease (COVID-19), with its beneficial effects reinforced by adding azithromycin, results of a recent study have shown.
Elvira Manzano, 22 Nov 2017
A blood pressure (BP) reading of 130/80 mm Hg or higher is the ‘new high’ in the latest AHA/ACC* hypertension guidelines, a threshold that is tighter than the JNC 7** cutpoint of 140/90 mm Hg for stage 1 hypertension in the general population. The change will mean more patients being labelled with hypertension.
Audrey Abella, 27 Mar 2020
The angiotensin receptor blocker (ARB) losartan did not improve inflammation, T-cell immune recovery, or fibrotic activity among older persons living with HIV (PLHIV) and viral suppression, according to data presented at CROI 2020.